A facile route to core-shell nanoparticulate formation of arsenic trioxide for effective solid tumor treatment
A facile route to core-shell nanoparticulate formation of arsenic trioxide for effective solid tumor treatment
复制标题
形成三氧化二砷核壳纳米颗粒的简便途径，用于有效治疗实体瘤
DOI：
10.1039/c5nr07860a
复制
发表时间：
2016
期刊：
影响因子：
6.7
通讯作者：
Gao Jinhao
中科院分区：
文献类型：
--
作者：
Zhang Zongjun;Liu Hanyu;Zhou Hualu;Zhu Xianglong;Zhao Zhenghuan;Chi Xiaoqin;Shan Hong;Gao Jinhao
三氧化二砷在治疗急性早幼粒细胞白血病（APL）方面取得了巨大的临床成功。然而，很难在其他癌症（如实体瘤）中复制成功，部分原因是快速的肾脏清除和剂量限制性毒性。纳米技术有望通过改变药物的药代动力学和将药物集中在所需部位来克服这些缺点。在此，我们报告了一种“一锅法”的方法来开发基于砷的纳米药物，通过原位涂层与多孔二氧化硅壳制备的砷纳米复合物。该方法可以很容易地复制和放大，因为不涉及复杂的合成和纯化步骤。这种核-壳包埋方法赋予纳米药物高负载量（57.9wt%）和延长的pH响应释放曲线，这对于增加肿瘤部位的药物浓度和提高药物疗效至关重要。基于这些独特的功能，纳米药物显着抑制实体肿瘤的生长，而没有不良副作用。因此，我们预期通过这种简单的合成途径产生的砷基纳米药物可能是实体瘤治疗的一种强大的替代策略。
Arsenic trioxide has achieved great clinical success in the treatment of acute promyelocytic leukemia (APL). However, it is difficult to replicate the success in other cancers, such as solid tumors, in part because of the rapid renal clearance and dose-limiting toxicity. Nanotechnology is expected to overcome these disadvantages through altering its pharmacokinetics and concentrating the drug at the desired sites. Herein, we report a “one-pot” method to develop arsenic-based nanodrugs by in situ coating the as-prepared arsenic nanocomplexes with porous silica shells. This process can be easily reproduced and scaled up because no complicated synthesis and purification steps are involved. This core–shell embedding method endows nanodrugs with high loading capacity (57.9 wt%) and a prolonged pH-responsive releasing profile, which is crucial to increase the drug concentration at tumor sites and improve the drug efficacy. Based on these unique features, the nanodrugs significantly inhibit the growth of solid tumors without adverse side effects. Therefore, we anticipate that the arsenic-based nanodrugs generated by this facile synthetic route may be a powerful and alternative strategy for solid tumor therapy.